Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trial

被引：0
|
作者：
Peyrin-Biroulet, L. [1 ,2 ]
Louis, E. [3 ]
Hisamatsu, T. [4 ]
Jamoul, C. [5 ]
Santermans, E. [5 ]
Harris, K. [6 ]
de Haas, A. [7 ]
Oortwijn, A. [8 ]
Feagan, B. [9 ]
机构：
[1] Hop Brabois, Dept Gastroenterol, Vandoeuvre Les Nancy, France
[2] Inserm, U954, Vandoeuvre Les Nancy, France
[3] Univ Hosp Liege, Dept Gastroenterol, Liege, Belgium
[4] Kyorin Univ, Dept Gastroenterol & Hepatol, Sch Med, Tokyo, Japan
[5] Galapagos NV, Biostat Dept, Mechelen, Belgium
[6] Galapagos NV, Med Evidence Generat Dept, Milan, Italy
[7] Galapagos NV, Clin Dev Dept, Leiden, Netherlands
[8] Galapagos NV, Med Affairs Dept, Leiden, Netherlands
[9] Western Univ, Div Gastroenterol, London, ON, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P736
引用
收藏
页码：866 / 866
页数：1
相关论文
共 39 条
  • [31] Fecal Calprotectin Levels, C-Reactive Protein Levels, and Partial Mayo Score as Early Predictors of Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Treated With Tofacitinib in a Phase 2 Study
    Dubinsky, Marla C.
    Hudesman, David P.
    Kulisek, Nicole
    Salese, Leonardo
    Paulissen, Jerome
    Su, Chinyu
    Magro, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S474 - S475
  • [32] EXPOSURE-RESPONSE ANALYSES TO SUPPORT DOSE SELECTION OF BMS-936557, A MONOCLONAL ANTIBODY TO IP-10, FOR A PHASE 2B STUDY IN PATIENTS WITH ULCERATIVE COLITIS
    Tao, X.
    Xu, L.
    Shi, R.
    Luo, A.
    Shen, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S62 - S63
  • [33] A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis
    Sands, B.
    Sandborn, W.
    Feagan, B. G.
    Lichtenstein, G.
    Zhang, H.
    Szapary, P.
    Panes, J.
    Vermeire, S.
    O'Brien, C.
    Dewey, J.
    Yang, Z.
    Johanns, J.
    Strauss, R.
    Marano, C.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S71 - S72
  • [34] Time to Upadacitinib treatment response over 16 weeks for patients with atopic dermatitis from Phase 2b randomized, placebo-controlled trial
    Reich, Kristian
    Guttman-Yassky, Emma
    Hu, Xiaofei
    Calimlim, Brian
    Teixeira, Henrique
    de Bruin-Weller, Marjolein
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 18 - 19
  • [35] SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS
    D'Haens, Geert R.
    Colombel, Jean Frederic
    Lichtenstein, Gary R.
    Charles, Lorna
    Petersen, AnnKatrin
    Ather, Shabana
    Kollengode, Kanthi
    Hsu, Kate
    Irving, Peter M.
    Danese, Silvio
    GASTROENTEROLOGY, 2021, 160 (06) : S35 - S35
  • [36] C-REACTIVE PROTEIN LEVELS AND PARTIAL MAYO SCORE AS EARLY PREDICTORS OF CLINICAL AND ENDOSCOPIC OUTCOMES IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB: A POST HOC ANALYSIS OF OCTAVE INDUCTION 1&2
    Dubinsky, Marla C.
    Hudesman, David
    Steinwurz, Flavio
    Kulisek, Nicole
    Salese, Leonardo
    Paulissen, Jerome
    Su, Chinyu
    de Leon, Dario Ponce
    Magro, Fernando
    GASTROENTEROLOGY, 2020, 158 (06) : S1196 - S1197
  • [37] Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials
    Panes, J.
    Loftus, E. V., Jr.
    Armuzzi, A.
    Siegmund, B.
    Sands, B. E.
    Boland, B. S.
    Kalabic, J.
    Lai, J. H.
    Sharma, D.
    Remple, V.
    Gonzalez, Y. Sanchez
    Lindsay, J. O.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1585 - I1586
  • [38] Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebocontrolled trial
    Mesinkovska, Natasha
    Shapiro, Jerry
    King, Brett
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB54 - AB54
  • [39] Improvement in patient-reported hair loss outcome measures in patients with alopecia areata treated with ritlecitinib: 48-week results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
    Sinclair, Rodney
    Mesinkovska, Natasha
    Mitra, Debanjali
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB69 - AB69
1234